A new device that automatically monitors blood glucose levels and adjusts insulin levels has received FDA approval. The device, manufactured by Dublin-based Medtronic PLC, is the first such system to gain the agency’s blessing.
The new MiniMed 670G hybrid closed-loop system is intended for people aged 14 years or older who have type 1 diabetes. Because it operates with a smart algorithm that learns an individual’s insulin needs and delivers appropriate basal doses 24 hours a day, little user input is required. Patients who use the system will only have to enter their mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.
Voelker R. “Artificial Pancreas” Is Approved. JAMA. 2016;316(19):1957. doi:10.1001/jama.2016.16344
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: